Help Therapeutics Raises $25 Million for iPSC Heart Failure/Oncology Therapies

Nanjing Help Therapeutics completed a $25 million Series C financing to develop its stem cell programs for heart failure and oncology immunotherapies. The company says its induced pluripotent stem cell (iPSC) technology offer a better alternative for cell therapies than current manual manufacturing systems. Help Therapeutics will use its iPSC technology to conduct heart cell injection trials and to start clinical trials of an immune cell therapy next year. The C round was led by Ming Bioventures and included Share Capital, Beisen Medical Fund, and Jolmo Capital. More details.... Share this with colleagues: // //